The FTC's enforcement action against NextMed revealed how subscription traps and misleading pricing harm GLP-1 patients. Here's what happened — and the checklist that protects you.
Key Takeaway: The FTC's action against NextMed is good news for patients who want to use GLP-1 telehealth safely. It signals that regulators are actively watching the industry and that bad actors will face consequences. The majority of GLP-1 telehealth providers operate legitimately — but this case is a useful reminder of what to watch out for when choosing one.
The Federal Trade Commission filed a complaint against NextMed (also operating as Mochi Health in some contexts — though Mochi Health is a distinct company; NextMed operated as a separate telehealth platform) alleging multiple deceptive and unfair business practices targeting GLP-1 patients.
The core allegations centered on what regulators described as "negative option" or subscription trap practices: patients who signed up for what appeared to be a low introductory offer were enrolled in ongoing subscription plans with significantly higher monthly costs that were difficult to cancel. The FTC alleged that cancellation processes were intentionally complicated, that customers were charged after attempting to cancel, and that pricing disclosures were misleading about true ongoing costs.
Additionally, the FTC alleged that NextMed's marketing made claims about the quality and supervision of medical care that the FTC characterized as misleading relative to the actual level of oversight provided to patients.
The case resulted in a settlement that included monetary relief for affected consumers and compliance requirements for NextMed's business practices going forward. The settlement terms required transparent pricing disclosure, simplified cancellation processes, and enhanced oversight requirements.
These providers are known for clear pricing, easy cancellation, and real physician oversight.
The GLP-1 telehealth market expanded at extraordinary speed from 2021 to 2025. Hundreds of new providers entered a market with enormous demand and, initially, minimal regulatory scrutiny. Some were excellent; some cut corners; some were actively predatory. The FTC action against NextMed was one of the clearest signals yet that regulators had caught up with the industry's growth.
The settlement matters for several reasons. First, it establishes precedent: the FTC is willing to act against GLP-1 telehealth companies specifically, not just against health fraud generally. Second, it creates compliance pressure across the industry — providers that relied on confusing pricing or difficult cancellations now face the risk of being next. Third, it creates a clear framework for what patients have a right to expect.
The vast majority of GLP-1 telehealth providers are operating legitimately, providing real medical oversight and fairly priced services. The NextMed case is a data point about what bad actors look like — not an indictment of the industry as a whole. Compounded GLP-1 access through telehealth has genuinely helped millions of patients afford therapy that would otherwise cost them $1,000+ per month out of pocket. That's a real benefit worth protecting.
The practices the FTC highlighted aren't unique to NextMed. Understanding the pattern helps you recognize it anywhere:
Before signing up with any GLP-1 telehealth provider, get clear answers to these six questions:
Every provider on this site has been vetted for licensing, pharmacy accreditation, and transparent pricing. Elevate Health is one of our most consistently transparent options.
Explore Elevate Health →Some in the GLP-1 space worry that FTC and FDA scrutiny will restrict access or raise prices. We think the opposite is more likely: clear standards and enforcement protect legitimate providers from being undercut by bad actors, protect patients from being harmed by predatory practices, and build the trust that makes the overall market healthier.
The compounded GLP-1 market exists because brand-name medications are unaffordable for most patients without insurance coverage. That's a legitimate and important role. Regulatory oversight that ensures quality, honest pricing, and real medical supervision strengthens that role — it doesn't undermine it.
For more on the legal landscape for compounded GLP-1s, see our detailed guide: Is Compounded Semaglutide Still Legal in March 2026?
All claims sourced from FTC filings, published regulatory documents, and named enforcement actions. No Fluff. Just Sources.
Transparent pricing · Easy cancellation